Drug makers & biotechDrug and biotech companies, with their PACs and trade groups. Pharmacies and distributors are under Other health companies.Business › Health
PAC (qualified)Lobbyist/registrant PACCorporationWashington, District of ColumbiaActive
“We use the power of leading-edge science to save and improve lives around the world.”
Merck & Co., Inc., the organization this committee is the political fund of, merck.com
Quoted from the committee's site, or its sponsor's or funder's where its own says nothing. Any side it takes is in its own words.
No published list of positions
Its sponsor’s site sums up what it stands for in the statement above, and publishes no list of positions beyond it.
Who it gives toWhich candidates and committees get its money?
Each part reads different filings, so counts and totals can differ.
Party support distribution$635K to 143 candidates
Direct PAC contributions and independent expenditures explicitly reported as support, by the party of the candidate they went to.
For candidates $635,000
Republican 60%Democratic 30%
Support by the party of the candidate
Party of the candidate
Candidates
Direct
Independent
Amount
Share
Republican
77
$383,500
$0
$383,500
60%
Democratic
45
$192,000
$0
$192,000
30%
Other or unresolved
21
$59,500
$0
$59,500
9.4%
Shown support
143
$635,000
$0
$635,000
100%
Contributions are reported money, not endorsements; a PAC giving to both parties is common.
Who this PAC gave to$1,056,000 in 376 payments
Every contribution on line 23 of the committee’s own Schedule B, which is the filing its summary totals are built from. That line covers federal candidates, party committees and other political committees alike, so a super PAC funding other super PACs appears here rather than under candidate giving.
By recipient
Line 23 contributions by kind and party of recipient
Recipient
Count
Amount
Democratic candidates
45
$192K · 18%
Republican candidates
76
$380K · 36%
Other or unresolved candidates
22
$63K · 6%
Other party committees
4
$105K · 9.9%
Other PACs and committees
49
$316K · 30%
All recipients
196
$1.1M
By the candidate’s state
Contributions to candidates by the candidate’s state
State
Candidates
Amount
California
16
$64K
Pennsylvania
8
$52K
North Carolina
9
$48K
Louisiana
6
$38.5K
New Jersey
6
$37K
Florida
8
$25K
Ohio
5
$24.5K
Kentucky
4
$23.5K
The largest 8 of 42 states.
Recipients 196
Show candidate activity and the money network
Candidate and election activity as the recipients filed it
Don Davis3 receipts, latest Sep 14, 2026Don Davis for NC · H2NC02287$10K
Steve Scalise2 receipts, latest Mar 4, 2026Scalise for Congress · H0LA01087$10K
Thomas H. Kean Jr.4 receipts, latest Oct 6, 2026Kean for Congress Inc · H0NJ07261$10K
Richard L. Hudson Jr.2 receipts, latest Mar 16, 2026Hudson for Congress · H2NC08185$10K
George J. Kelly Jr.5 receipts, latest Oct 6, 2026Mike Kelly for Congress · H0PA03271$10K
Candidate contribution rows come from candidate committee Schedule A filings, the same rows the party chart above counts.
Committee money network
Money moving between this committee and other committees, matched on FEC committee ID rather than the name each filing was typed under. Both sides exclude memo entries. The figures here count each committee once, from the itemized transfers read for this section, so they will not match the payment counts under Who this PAC gave to.
Committees funding this one
Committees that reported giving to this one on their own Schedule A filings, grouped by the giver’s committee ID.
No committee-to-committee receipts were itemized this cycle.
Committees this one funds
Disbursements this committee itemized to another committee: candidate contributions, party transfers and payments alike, not contributions only.
Committees this one funds
Name
Amount
NRSCParty committee (qualified) · Connected to YOUNG VICTORY COMMITTEE · 2 payments
A donor who gave several times appears once. The 12 largest donors by total given are listed. In all, 6,468 itemized contributions were filed this cycle, totaling $1.1M. FEC contributor lists are public records and cannot be used for commercial solicitation.
Unitemized ($200 or less)Donors who have given $200 or less this cycle, so the FEC does not itemize (name) them.$196,43715%
Refunds and rebatesMoney coming back to the committee: rebates and refunds of what it spent, contributions it made that were returned, and loans it made that were repaid.$9,5000.7%
Total reported receipts $1,351,293
Every dollar the committee reported receiving this cycle, split by the source the FEC filing attributes it to. FEC filings through Oct 14, 2026.
Who donated: where they live, their employers and jobs
Where the donors live $1,144,748 placed by state
Loading the map
Tap or hover over a state, or focus the map and use the arrow keys, to read its total. Ctrl or ⌘ and scroll to zoom.
under $21.5K
$21.5K+
$85.9K+
$193.2K+
$343.4K+
none
Top states
Top donor states
Name
Amount
Pennsylvania3,760 contributions · 47%
$536,565
New Jersey1,766 contributions · 37%
$421,840
District of Columbia343 contributions · 5.3%
$60,121
North Carolina219 contributions · 4%
$45,513
Massachusetts149 contributions · 3.4%
$38,931
Kansas157 contributions · 2.3%
$26,118
California33 contributions · 1.1%
SpendingWhere does the money go?
How the spending splits $1,519,034 reported
Tap a row with to see who was paid.
Contributions to candidates and other committeesMoney given to federal candidates, party committees and other PACs.$1,063,50070%
Paid to
NRSC2 payments · latest Mar 4, 2026 · CONTRIBUTION$30,000
DSCC2 payments · latest Mar 4, 2026 · CONTRIBUTION$30,000
NRCC2 payments · latest Mar 4, 2026 · CONTRIBUTION$30,000
Every dollar this committee reported spending this cycle, split by the lines it reports against. Open a line to see who was actually paid on it. FEC filings through Oct 14, 2026.
What the payments were for $1,509,727 itemized
Tap a row with to see what was paid for.
Given to othersContributions to other candidates, party committees, and PACs.$1,212,82580%
Filed as
CONTRIBUTION$1,212,825
Paid to
Merck Newyork State PAC$63,650
NRSC$30,000
DSCC$30,000
NRCC$30,000
Merck & Co., Inc. Employees Missouri PAC Federal Committee$20,225
Chamber PAC$20,000
OtherPayments whose filed description does not match any category above. Every one is listed so it can be read directly.$295,61520%
Filed as
JOSEPH PITTMAN, STATE SENATE 41ST PA$9,150
MATTHEW BRADFORD, STATE HOUSE 70TH PA$7,550
TRACY PENNYCUICK, STATE SENATE 24TH PA$7,000
ANN JOHNSON, STATE HOUSE 134TH TX$6,000
JOSHUA STEIN, GOVERNOR NC$6,000
KATIE HOBBS, GOVERNOR AZ
Spending over time
$1.5M spent from Jan 2025 to Oct 2026. Most in one report: $209K, September 2026.
$1.5M
Jan 2025Oct 2026
The running total of what the committee’s FEC reports say it spent, independent expenditures included, with a point at the end of each report. The line is straight between reports because a report gives one total for its whole period.
Each report’s total
Oct 1 – Oct 14, 2026$195,843
September 2026$208,962
August 2026$57,492
July 2026$77,013
June 2026$66,235
May 2026$80,840
April 2026$77,300
March 2026$186,052
February 2026$13,460
January 2026$0
December 2025$33,773
November 2025$64,286
October 2025$0
September 2025$127,000
August 2025$12,500
July 2025$1,500
June 2025$62,250
May 2025$66,000
April 2025$0
March 2025$35,500
February 2025$160,000
January 2025$0
Show other payments: transfers, refunds and the rest
601 PENNSYLVANIA AVE., NWNORTH BUILDING, SUITE 1200WASHINGTON, DC, 20004
Audits and penalties
None published by the FEC
LobbyingWhat does its sponsor lobby on?
What Merck & Co Inc lobbies on 2026 reports
Besides giving through its PAC, Merck & Co Inc pays lobbyists to press Congress and federal agencies. Each quarter it, or a firm it hires, files a public report under the Lobbying Disclosure Act saying which topics it worked on, what it spent, and whom it contacted. This is what those reports say.
Spent on lobbying in 2026
$8.8M
Quarterly reports read
35
Bills it named
12
Topics it lobbied on
Each report files its work under official topics. The bar shows how often each topic came up across the reports; open one to read what was filed under it. Naming a bill says the organization lobbied on it, not which side it took.
Medicare/Medicaidin 27 report entries · 7 bills named
In its own words
Issues relating to, One Big Beautiful Bill Act (P.L. 119-21), issues related to health care;
Medicare;
Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program;
Drug pricing;
Cost and value of medicines: Drug pricing and reimbursement issues;
FY-2027 Budget and Appropriations Legislation;
Medicaid drug rebate program (MDRP).
Drug pricing proposals.
Pharmacy Benefit Manager reform proposals.
H.R. 1, "One Big Beautiful Bill Act" implementation and ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D;
Issues related to Most Favored Nation (MFN) drug pricing proposals.
ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D;
Issues related to Medicare and Medicaid coverage and reimbursement;
Issues related to cyclic peptides;
Issues related to Most Favored Nation (MFN) drug pricing proposal;
Issues related to the implementation of the Inflation Reduction Act of 2022;
Issues related to Senate Finance Dear Colleague process
Issues related to Senate Finance Dear Colleague process;
H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Issues related to Medicare Part D and Part B Pricing Reform;
Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act;
Issues related to H.R. 8857 - Next GEN Act of 2026;
Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program;
Drug pricing;
Drug pricing and reimbursement issues;
Cost and value of medicines;
Vaccine issues;
Package inserts and e-labeling;
Package inserts, labeling issues, and e-labeling authorization legislation;
Pharmaceutical supply channel issues;
Drug shortages issues;
Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions;
One Big Beautiful Bill Act (P.L. 119-21), issues related to health care;
FY-2027 Budget and Appropriations Legislation;
Budget reconciliation drug pricing provisions;
Commerce Justice, Science, and related agencies appropriations legislation for 2026;
Interior, Environment, and related agencies appropriations legislation for 2026;
Intellectual property protection and trade issues;
Animal Health Policy Issues;
Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability;
General pharmaceutical issues;
Vaccine Injury Compensation Program (VICP);
Vaccine Policy;
Pharmacy Benefit Manager (PBM) policy issues;
Taxation/Internal Revenue Codein 13 report entries · 1 bill named
In its own words
Issues related to corporate and international taxation.
Issues related to OECD Pillar 1 and Pillar 2 negotiations, agreements, implementation, and reporting related to the taxation of global income.
Issues related to IRC sections 11, 951A, and 250.
Issues relating to, Tax reform and tax policy, generally;
Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes;
Tax Cuts and Jobs Act (P.L. 115-97), provisions relating to tax reform.
Issues related to tax reform; R&D tax credit; international taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.
Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21.
Issues related to tax reform; international taxation.
Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP. Issues related to China WRT the BINSA bill.
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP.
Issues related to intellectual property protections.
Issues related to tariffs.
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
Executive Office of the President (EOP)
Office of Management & Budget (OMB)
White House Office
U.S. Trade Representative (USTR)
Pharmacyin 6 report entries
In its own words
General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues.
Monitor issues related to drug pricing.
Issues related to drug pricing.
Offices it contacted
SENATE
HOUSE OF REPRESENTATIVES
Animalsin 3 report entries
In its own words
Issues relating to, Agriculture, Rural Development , Food and Drug Administration, and Related Agencies Appropriations Bill;
Commerce, Justice, Science, and Related Agencies Appropriations Bill, 2026;
Interior, Environment, and Related Agencies Appropriations Bill 2026;
United States Department of Agriculture, Animal and Plant Health Inspection Service, Final Rule: Use of Electronic Identification Ear tags as Official Identification in Cattle and Bison.
Issues relating to, Animal Health Policy Issues;
Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability;
Agriculture, Rural Development , Food and Drug Administration, and Related Agencies Appropriations Bill, 2026;
Interior, Environment, and Related Agencies Appropriations Bill 2026.
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
Budget/Appropriationsin 3 report entries
In its own words
Federal budget issues
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
Copyright/Patent/Trademarkin 3 report entries
In its own words
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
Who did the lobbying
The organization’s own reports give its total lobbying costs, including any firms it hired; each firm reports what this client paid it.
Merck & Co, Inc.Its own staff · 3 reports$8.8M
The Nickles Group, LLCLobbying firm · 3 reports$210K
B Hall Strategies, LLCLobbying firm · 3 reports$90K
The Washington Tax & Public Policy GroupLobbying firm · 2 reports$10K
Contributions on the LD-203 report
Reported twice a year by the lobbying filer. $246.5K is political giving that also appears in FEC filings.
DCCC$15K
DSCC$15K
NRCC$15K
NRSC$15K
US Senator Roger Marshall$10K
US Representative Brett Guthrie$5K
US Representative James Johnson$5K
US Representative Jason Smith$5K
US Representative John Joyce$5K
US Representative Morgan Griffith$5K
Matched by name: these reports are filed for “MERCK & CO INC”, found by searching “MERCK”. Lobbying and FEC records share no ID, so an organization that lobbies under another name is missed. Source: LDA.gov, accessed Nov 9, 2026. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
MERCK & CO., INC., EMPLOYEES POLITICAL ACTION COMMITTEE (MERCK PAC)
Filings covered
Through Oct 14, 2026
Data source
FEC bulk filing data
Merck & Co., Inc., Employees PAC is registered with the Federal Election Commission as a PAC (qualified). It is a lobbyist/registrant PAC. Its FEC record names Merck & Co., Inc. as an affiliate. Official FEC summary: Federal Election Commission committee record.
Merck & Co., Inc., Employees PAC is matched to organization records using the FEC committee identity, structured identifiers, and corroborated organization data.
Structured organization facts
Identity match
Exact FEC committee ID in LittleSis
Match confidence
high
Source coverage
Official pages captured
21
LittleSis classifications
Organization, Political Fundraising Committee, Other Campaign Committee
$1.1M across 192 recipient committees, or 70% of everything this committee reports spending. The largest 12 are shown.
Built from FEC Schedule A and Schedule B filings for the selected cycle. A committee only appears here if the money was itemized under its FEC committee ID.
$13,154
Nebraska17 contributions · 0.1%
$1,341
By the state each contributor wrote on the filing. The FEC aggregates every Schedule A line together, so one committee or organization transfer can account for a whole state. Contributors who have given $200 or less this cycle are not itemized and cannot be placed on a map. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total.
Donors’ employers as filed
Donors’ employers
Employer as filed
Amount
Merck Sharp & Dohme6,468 contributions · 100% of ranked
$1,143,233
A further $1,515 came from donors whose answer names no employer (blank), so it is not ranked. Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($196,437) are not itemized, so no employer or occupation is filed for them.
Donors’ occupations as filed
Donors’ occupations
Occupation as filed
Amount
Exec DIR Policy/govern Relations227 contributions · 3.7% of ranked
$41,428
DIR Policy/govern Relations314 contributions · 3.5% of ranked
$38,615
SVP Clinical Research53 contributions · 2.3% of ranked
$25,523
VP Research Science67 contributions · 2.3% of ranked
$25,204
SVP Business Unit55 contributions · 1.8% of ranked
$20,246
VP Policy/govern Relations52 contributions · 1.6% of ranked
$18,126
SVP Regulatory Affairs44 contributions · 1.6% of ranked
$17,935
VP HR Business Partner69 contributions · 1.6% of ranked
$17,632
A further $1,515 came from donors whose answer names no occupation (blank), so it is not ranked. Ranked from the largest 200 of 201 occupation spellings filed; each share is of the money in those. Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($196,437) are not itemized, so no employer or occupation is filed for them.
Merck Newyork State PAC2 payments · latest May 28, 2026 · CONTRIBUTION$63,650
Merck & Co., Inc. Employees Missouri PAC Federal Committee3 payments · latest Jun 3, 2026 · CONTRIBUTION$20,225
Chamber PAC4 payments · latest Oct 7, 2026 · CONTRIBUTION$18,000
Taxes, fees, and bank chargesPayroll and income taxes, filing fees, bank and merchant processing charges.$787<0.1%
Filed as
CHECK PRINTING FEE$787
Paid to
Harland Clarke$787
Digital and technologyWebsites, hosting, software subscriptions, databases, email, and texting platforms.$500<0.1%
Filed as
JOSEPH WEBSTER, STATE HOUSE 150TH PA$500
Paid to
Friends of Joe Webster$500
Total itemized disbursements $1,509,727
Every itemized payment the committee reported this cycle, sorted by what it said each one was for. The categories are ours; the wording they are matched against is the committee’s own. Open a category to read the filed descriptions and who was paid. FEC filings through Oct 14, 2026.
All 824 itemized payments filed this cycle. Spending below the itemization threshold is not filed line by line.
Largest vendors
Largest vendors
Name
Amount
Merck Newyork State PAC2 payments · 4.2% of all spending
Senate Republican Campaign Committee2 payments · 0.8% of all spending
$12,000
The people, firms and committees paid the most, across every kind of payment. Each share is of everything the committee reported spending this cycle, not only the itemized payments above. A payee that is itself a committee links to its own profile.
Merck Newyork State PAC2 payments, latest May 28, 2026CONTRIBUTION$63.7K
Merck & Co., Inc. Employees Missouri PAC Federal Committee3 payments, latest Jun 3, 2026CONTRIBUTION$20.2K
Chamber PAC4 payments, latest Oct 7, 2026CONTRIBUTION$18K
Friends of Joe Pittman4 payments, latest Aug 13, 2026JOSEPH PITTMAN, STATE SENATE 41ST PA$9.2K
Transfers, refunds, and everything else the committee itemized outside candidate giving. 447 payments totaling $452.9K.
Pharmacy Benefit Manager reforms;
Food and Drug Administration issues;
Public Health Issues;
Most Favored Nation (MFN) drug pricing;
Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients;
International competition in biopharmaceuticals.
S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act;
Intellectual property and trade issues;
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
S.891, Bipartisan Health Care Act;
Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety;
340B Program.
Issues related to drug pricing.
General pharmaceutical issues.
Pubic health issues.
Issues related to MFN.
Appropriations and budget legislation for FY27.
Reconciliation.
Issues related to supply chain and shortages.
Issues on vaccine policy.
PBM reform.
FDA issues.
IRA Implementation.
Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues. Issues related to TrumpRX.